Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Neuronetics, Inc.NASDAQ: STIM

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue rises 6.1% from a year ago

Deferred revenue stood at $833K at the end of Q1 FY2026, up 6.1% from a year earlier and up 10.6% from the prior quarter. Over 3 fiscal years it compounded at -27.5% a year.

Context

  • Deferred revenue amounted to 0.7% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether deferred revenue keeps rising in the next quarterly balance sheet after a +6.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$833K+10.6% QoQ
Last fiscal yearDec 2025
$753K-22.7% YoY
Year agoMar 2025
$785K+6.1% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.1%——
1 year-22.7%——
3-year CAGR-27.5%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
753K USD
Year-over-year change
-22.7%
4-year CAGR
-25.9%

Deferred Revenue vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +6.1% is the 4th highest of 8, against a peer median of -26.8%.
  • Deferred revenue amounts to 0.7% of total assets for STIM, versus a peer median of 0.7%.
STIM Competitors
Deferred Revenue for STIM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CATXPerspective Therapeutics, Inc.Mar 2026$26.6M USD——6.5%
PREPrenetics Global LimitedMar 2026$2.95M USD-52.4%-18.4%1.7%
OABIOmniAb, Inc.Mar 2026$2.94M USD+70.4%-27.2%1.0%
NYXHNyxoah S.A.Mar 2026€1.12M EUR+205.5%—1.1%
OSUROraSure Technologies, Inc.Mar 2026$872K USD-65.3%-12.6%0.2%
CDXSCodexis, Inc.Mar 2026$866K USD+97.7%-20.1%0.7%
STIMNeuronetics, Inc.Mar 2026$833K USD+6.1%-27.5%0.7%
PROFProfound Medical Corp.Mar 2026$465.53K USD-26.8%—0.6%
SGMOSangamo Therapeutics, Inc.Mar 2026$402K USD-94.7%-74.1%0.7%
ATLNAtlantic International Corp.Dec 2025$0 USD——0.0%
Peer median (excluding STIM) —-26.8%-20.1%0.7%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents94.14M70.34M59.68M19.46M34.13M
Short-term Investments2.2M1.54M905K206K225K
Net Receivables7.78M13.82M17.84M24.29M16.89M
Inventory6.56M8.9M8.09M4.25M4.33M
Other Current Assets3.09M2.17M4.77M6.85M5.97M
Total Current Assets115.33M98.77M93.79M58.12M61.55M
Property, Plant & Equipment (Net)5.1M5.32M4.78M33.34M28.03M
Goodwill00018.63M23.62M
Intangible Assets00019.61M18.15M
Long-term Investments1.7M1.22M661K86K249K
Tax Assets00000
Other Non-current Assets19.09M11.58M16.6M11.12M9.95M
Total Non-current Assets25.89M18.12M22.04M82.78M80M
Total Assets141.22M116.88M115.83M140.9M141.55M
Account Payables4.3M2.43M4.75M11.08M10.74M
Short-term Debt013.13M005.56M
Tax Payables664K659K818K619K0
Deferred Revenue2.5M1.98M1.62M974K753K
Other Current Liabilities5.09M11.2M8M8.95M4.86M
Total Current Liabilities15.7M33.2M19.81M31.27M30.52M
Long-term Debt35.34M22.83M59.28M55.15M65.81M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.47M829K200K2K48K
Other Non-current Liabilities00000
Total Non-current Liabilities40.35M26.63M61.83M77.84M84.79M
Total Liabilities56.05M59.82M81.64M109.1M115.31M
Common Stock264K273K291K557K690K
Retained Earnings(308.73M)(345.89M)(376.08M)(419.79M)(458.79M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest0004.09M3.86M
Total Equity85.18M57.06M34.19M31.8M26.24M
Total Debt39.54M39.75M62.47M82.63M90.3M
Net Debt(54.6M)(30.6M)2.8M63.17M56.17M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.